|
1.
|
|
18 p, 3.4 MB |
Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection
/
Barmada, Anis (Department of Medical Genetics. University of Cambridge) ;
Handfield, Louis-François (Wellcome Sanger Institute (Regne Unit)) ;
Godoy-Tena, Gerard (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
de la Calle-Fabregat, Carlos (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ciudad, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Arutyunyan, Anna (Wellcome Sanger Institute (Regne Unit)) ;
Andrés-León, Eduardo (Instituto de Parasitología y Biomedicina "López-Neyra") ;
Hoo, Regina (Wellcome Sanger Institute (Regne Unit)) ;
Porter, Tarryn (Wellcome Sanger Institute (Regne Unit)) ;
Oszlanczi, Agnes (Wellcome Sanger Institute (Regne Unit)) ;
Richardson, Laura (Wellcome Sanger Institute (Regne Unit)) ;
Calero-Nieto, Fernando (Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute. University of Cambridge) ;
Wilson, Nicola K. (Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute. University of Cambridge) ;
Marchese, Domenica (Centre de Regulació Genòmica) ;
Sancho-Serra, Carmen (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ruiz-Sanmartin, Adolfo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ferrer, Ricard (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ruiz-Rodriguez, Juan Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez Gallo, Mónica (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Munera-Campos, Mónica (Institut Germans Trias i Pujol) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol) ;
Göttgens, Berthold (Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute. University of Cambridge) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Prigmore, Elena (Wellcome Sanger Institute (Regne Unit)) ;
Casafont-Solé, Ivette (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Solanich, Xavier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sánchez-Cerrillo, Idelfonso (Department of Immunology. Hospital Universitario La Princesa) ;
González-Álvaro, Isidoro (Rheumatology Service. Hospital Universitario La Princesa) ;
Raimondo, Maria Gabriella (Deutsches Zentrum Immuntherapie. Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen) ;
Ramming, Andreas (Deutsches Zentrum Immuntherapie. Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen) ;
Martin, Javier (Instituto de Parasitología y Biomedicina "López-Neyra") ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ballestar, Esteban (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vento-Tormo1, Roser (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Rodríguez-Ubreva, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
In COVID-19, hyperinflammatory and dysregulated immune responses contribute to severity. Patients with pre-existing autoimmune conditions can therefore be at increased risk of severe COVID-19 and/or associated sequelae, yet SARS-CoV-2 infection in this group has been little studied. [...]
2024 -  10.1002/eji.202350633
European Journal of Immunology, Vol. 54 Núm. 1 (january 2024) , p. 2350633
|
|
|
2.
|
|
19 p, 7.5 MB |
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab
/
Granell-Geli, Júlia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Izquierdo-Gracia, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sellés-Rius, Ares (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mansilla Lopez, Maria Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Brieva Ruiz, Luis (Hospital Universitari Arnau de Vilanova) ;
Sotoca Fernández, Javier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Mañé-Martínez, María Alba (Hospital Universitari Joan XXIII de Tarragona) ;
Moral, Ester (Hospital de Sant Joan Despí Moisès Broggi) ;
Bragado, Irene (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Goelz, Susan (Biogen Idec) ;
Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. [...]
2021 - 10.3390/jpm11121347
Journal of personalized medicine, Vol. 11 (december 2021)
|
|
|
3.
|
|
|
4.
|
|
22 p, 2.2 MB |
Paving the way towards an effective treatment for multiple sclerosis : advances in cell therapy
/
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Presas Rodríguez, Sílvia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
González-Larreategui, Íñigo (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Fondelli, Federico (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Djedovic, Neda (University of Belgrade. Department of Immunology) ;
Iwaszkiewicz-Grzes, Dorota (Poltreg S.A., Gdańsk, Poland) ;
Chwojnicki, K. (Medical University of Gdańsk. Department of Anaesthesiology & Intensive Care) ;
Miljković, Đ. (University of Belgrade. Department of Immunology) ;
Trzonkowski, P. (Poltreg S.A., Gdańsk, Poland) ;
Ramo-Tello, Cristina (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2. 5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. [...]
2021 - 10.1038/s41423-020-00618-z
Cellular and Molecular Immunology, Vol. 18 (may 2021) , p. 1353-1374
|
|
|
5.
|
|
11 p, 2.0 MB |
Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment
/
Mansilla Lopez, Maria Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Navarro-Barriuso, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quirant, Bibiana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramo-Tello, Cristina (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing-remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. [...]
2019 - 10.1111/cns.13142
CNS neuroscience & therapeutics, Vol. 25 (2019) , p. 995-1005
|
|
|
6.
|
|
14 p, 1.9 MB |
MAP7 and MUCL1 are biomarkers of Vitamin D3-induced tolerogenic dendritic cells in multiple sclerosis patients
/
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ardiaca-Martínez, Alicia (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Presas-Rodríguez, Silvia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ten Brinke, Anja (Amsterdam UMC. University Medical Center) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
The administration of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases, such as multiple sclerosis (MS). Specifically, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most widely studied approaches, as it has evidenced significant immune regulatory properties, both in vitro and in vivo. [...]
2019 - 10.3389/fimmu.2019.01251
Frontiers in immunology, Vol. 10 (June 2019) , art. 1251
|
|
|
7.
|
|
11 p, 861.1 KB |
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS) : A harmonised study protocol for two phase i clinical trials comparing intradermal and intranodal cell administration
/
Willekens, Barbara (University of Antwerp. Laboratory of Experimental Hematology. Vaccine and Infectious Disease Institute) ;
Presas-Rodríguez, Silvia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Derdelinckx, Judith (University of Antwerp. Laboratory of Experimental Hematology. Vaccine and Infectious Disease Institute) ;
Lee, Wai-Ping (University Hospital Antwerp (Bèlgica)) ;
Nijs, Griet (University Hospital Antwerp (Bèlgica)) ;
De Laere, Maxime (University of Antwerp. Laboratory of Experimental Hematology. Vaccine and Infectious Disease Institute) ;
Wens, Inez (University of Antwerp . Laboratory of Experimental Hematology. Vaccine and Infectious Disease Institute) ;
Cras, Patrick (University Hospital Antwerp (Bèlgica)) ;
Parizel, Paul (University Hospital Antwerp (Bèlgica)) ;
Van Hecke, Wim (Icometrix NV) ;
Ribbens, Annemie (Icometrix NV) ;
Billiet, Thibo (Icometrix NV) ;
Adams, Geert (C-Clear Partners) ;
Couttenye, Marie-Madeleine (University Hospital Antwerp (Bèlgica)) ;
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Lopez-Diaz De Cerio, Ascensión (Clínica Universidad de Navarra) ;
Inogés, Susana (Clínica Universidad de Navarra) ;
Prosper, Felipe (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Kip, Anke (Lygature Utrecht) ;
Verheij, Herman (Lygature Utrecht) ;
Gross, Catharina C. (University of Munster. Department of Neurology) ;
Wiendl, Heinz (University of Munster. Department of Neurology) ;
Van Ham, Marieke (University of Amsterdam. Academic Medical Centre-AMC) ;
Ten Brinke, Anja (University of Amsterdam. Academic Medical Centre-AMC) ;
Barriocanal, Ana María (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Massuet-Vilamajó, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hens, Niel (University of Antwerp. Centre for Health Economic Research and Modelling Infectious Diseases) ;
Berneman, Zwi (University of Antwerp. Center for Cell Therapy and Regenerative Medicine) ;
Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cools, Nathalie (University Hospital Antwerp (Bèlgica)) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Introduction Based on the advances in the treatment of multiple sclerosis (MS), currently available disease-modifying treatments (DMT) have positively influenced the disease course of MS. However, the efficacy of DMT is highly variable and increasing treatment efficacy comes with a more severe risk profile. [...]
2019 - 10.1136/bmjopen-2019-030309
BMJ open, Vol. 9, Issue 9 (July 2019) , art. e030309
|
|
|
8.
|
|
10 p, 1.6 MB |
Th1Th17CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment
/
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Presas-Rodriguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Hervas-Garcia, Jose Vicente (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Brieva Ruiz, Luis (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Moral-Torres, Ester (Hospital de Sant Joan Despí Moisès Broggi) ;
Cano, Antonio (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Munteis, Elvira (Hospital del Mar (Barcelona, Catalunya)) ;
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment, by flow cytometry. [...]
2019 - 10.1155/2019/8147803
Mediators of Inflammation, Vol. 2019 (2019) , art. 8147803
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
